Muscle power is essential – always and everywhere.
Our muscles allow us to laugh and hug each other. Without them, we cannot walk, lift a cup, swallow, or even breathe.
Major loss of muscle function forces patients out of work and leaves them facing continuously decreasing quality of life and premature death. Muscle impairment can be a result of congenital malformation, trauma, hereditary muscular dystrophies, acute and/or critical conditions including cancer, or aging.
Until today, most patients with muscle disorders are treated with palliative medicine.
MyoPax is dedicated to radically improving this landscape. We aim to restore muscle function in local defects and muscle wasting disorders by delivering effective muscle regeneration therapies.
Vanguard stem cell manufacturing, cell engineering and gene-editing technologies are the pillars of our nascent product platforms.
MyoPax is a spin-off from the Muscle Research Unit of the Charité Universitätsmedizin and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association in Berlin (Website: Muscle Research Unit). Upon its launch in 2022, MyoPax joined the BioInnovation Institute in Copenhagen. We envisage becoming the international leader in biological muscle therapy.
We have more than 30 years of relevant experience in human skeletal muscle research and development. We are passionate about our mission and determined to succeed. We are empowered by strong science, state-of-the-art technology and preeminent clinical expertise.